---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-035666"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2026-07-31T21:00:19+00:00"
generated_at: "2026-07-31T21:02:33.332502+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics effects 1-for-16 reverse stock split to maintain NYSE American listing

## Summary
- Reverse stock split at 1-for-16 ratio effective July 30, 2026; trading begins July 31 under symbol CLDI.
- Post-split shares outstanding: ~2.45M Common Stock and 9,375 Non-Voting Common Stock.
- Split approved by stockholders on June 12, 2026; no fractional shares issued.
- New CUSIP number 320703 507 assigned to Common Stock.
- Purpose: increase per-share price and support continued listing on NYSE American.

## SEC filing metadata
- accession: 0001493152-26-035666
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2026-07-31T21:00:19+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/0001493152-26-035666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-035666
- JSON: https://secwatch.observer/filing/0001493152-26-035666.json
- Plain text: https://secwatch.observer/filing/0001493152-26-035666.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.